A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer

Brief description of study

If you have been diagnosed with advanced, metastatic, non-small cell lung cancer (NSCLC), you may qualify for this study. The main goal of this study is to test the safety and effectiveness of an investigational drug JNJ-61186372 for treating patients with your type of cancer.


Clinical Study Identifier: s17-01799
ClinicalTrials.gov Identifier: NCT02609776
Principal Investigator: Joshua K Sabari
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.